Neuroimmunological Registries in Germany by Thiel, S. et al.
Thiel S et al. Neuroimmunological Registries in Germany. Neurology International Open 2018; 2: E25–E39
Review
Thiel S et al. Neuroimmunological Registries in Germany. Neu- rology International Open 2017; 00: 00–00
Neuroimmunological Registries in Germany
  
Authors
S. Thiel1, F. Leypoldt2, 3, L. Röpke4, K. P. Wandinger2, 5, T. Kümpfel6, O. Aktas7, O. von Bismarck1, A. Salmen1, 8,  
B. Ambrosius1, G. Ellrichmann1, G. Antony9, T. Dankowski10, A. Ziegler10, 11, 12, A. Stahmann13, C. Meyer13,  
K. Eichstädt13, K. Buckow14, T. Meißner14, J. Thibaut15, L. Khil15, K. Berger15, R. Gold1, K. Hellwig1
Affiliations
1 Neurologische Klinik, St. Josef Hospital, Ruhr-Universität 
Bochum
2 Bereich Neuroimmunologie, Institut für Klinische 
Chemie, Universitätsklinikum Schleswig-Holstein Kiel/
Lübeck
3 Klinik für Neurologie, Universitätsklinikum 
 Schleswig-Holstein Kiel
4 Klinik für Neurologie, Universitätsklinikum Jena
5 Klinik für Neurologie, Universitätsklinikum 
 Schleswig-Holstein Lübeck
6 Institut für klinische Neuroimmunologie, 
 Ludwig- Maximilians-Universität, München
7 Klinik für Neurologie, Medizinische Fakultät, 
 Heinrich-Heine-Universität Düsseldorf
8 Universitätsklinik für Neurologie, Inselspital, 
 Universitätsspital Bern, Universität Bern, Schweiz
9	 Central	Information	Office	(CIO	KNP),	Universität	
Marburg
10 Institut für Medizinische Biometrie und Statistik, 
Universität zu Lübeck, Universitätsklinikum 
 Schleswig-Holstein, Campus Lübeck, Lübeck
11 ZKS Lübeck, Universität zu Lübeck, Lübeck
12 School of Mathematics, Statistics and Computer Science, 
University	of	KwaZulu-Natal,	Pietermaritzburg,	South	
Africa
13	MS	Forschungs-	und	Projektentwicklungs-gGmbH,	
Hannover
14 Institut für Medizinische Informatik, Universitätsmedizin 
Göttingen
15 Institut für Epidemiologie und Sozialmedizin, 
 Westfälische Wilhelms-Universität Münster
Key words
neuroimmunological registries, autoimmune encephalitis, 
neuromyelitis optica spectrum disorders, multiple sclerosis
Bibliography
DOI https://doi.org/10.1055/s-0043-108830
Neurology International Open 2018; 2: E25–E39
©	Georg	Thieme	Verlag	KG	Stuttgart	·	New	York 
ISSN 2511-1795
Correspondence
PD	Dr.	Kerstin	Hellwig
Neurologische Klinik
St. Josef Hospital
Ruhr-Universität Bochum
Gudrunstr.	56
44791 Bochum
k.hellwig@klinikum-bochum.de
ABSTR ACT
Several neuroimmunological registries have been established 
in	Germany	during	the	last	10	years.	The	common	aim	is	to	
investigate	the	course	of	different	diseases,	mainly	under	var-
ious therapeutic conditions, to identify predictive factors as 
well	as	the	side	effects	of	immunomodulating	therapies.	Six	
nationwide neuroimmunological registries will be presented 
in	this	article.	The	German	Network	for	Research	on	Autoim-
mune	Encephalitis	(GENERATE)	with	more	than	40	participating	
clinical	centers	and	570	documented	patients	(September	
2016)	collects	data	and	biomaterials	of	autoimmune	enceph-
alitis	with	known	and	unknown	antibodies.	The	registry	coor-
dinates and mediates between scientists and clinicians and acts 
as a platform for the development of guidelines and proce-
dures.	The	neuromyelitis	optica	study	group	(NEMOS)	has	es-
tablished a national registry for patients with neuromyelitis 
optica and neuromyelitis optica spectrum disorders. In addition 
to 22 academic hospitals, 17 regional hospitals and several 
practices are participating. Currently, 250 patients are enrolled. 
Moreover, NEMOS is now establishing a prospective patient 
cohort	(NationNMO)	within	the	competence	network	multiple	
sclerosis. Current research focuses on treatment strategies for 
relapses	and	interval	therapy	of	neuromyelitis	optica.	The	com-
petence network multiple sclerosis has initiated a multi-center, 
prospective cohort study of patients with clinically isolated 
syndrome	(CIS)	or	relapsing-remitting	multiple	sclerosis	(MS)	
(NationMS),	with	the	aim	of	long-term	follow-up	and	clinical	
and paraclinical characterization of the patients. Between Au-
gust 2010 and December 2014, 1,212 patients in 22 universi-
ty und non-university centers were enrolled in the NationMS 
cohort. Standardized clinical data as well as biomaterial and 
MRI	images	were	collected	and	stored.	The	German	MS	Socie-
ty	(DMSG,	Bundesverband	e.V.)	established	in	2001	a	long-
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term	project	to	obtain	a	consistent	and	reliable	overview	of	MS	
patients	in	Germany.	Since	2014	the	registry	has	been	revised	
comprehensively, with the main purpose of establishing a per-
manent data repository for healthcare research while ensuring 
the collection, storage and provision of data over decades and 
enabling the description of long-term outcomes. Currently, 
more	than	170	German	centers	are	participating	and	over	
48,000 patients are enrolled in the registry. Since 2013, the 
competence network multiple sclerosis has established the 
immunotherapy	registry	REGIMS	with	the	objective	to	obtain	
information on incidence, type and characteristics of adverse 
events of new immunomodulating therapies for patients with 
multiple sclerosis or clinical isolated syndrome. As of January 
2017 more than 700 patients have been recruited from 36 ac-
tive	centers.	The	German	Multiple	Sclerosis	and	Pregnancy	
Registry aims to obtain safety information of disease modifying 
drug exposure during pregnancy. In addition to safety aspects, 
disease course during pregnancy and postpartum and the iden-
tification	of	predictors	of	disease	activity	are	investigated.	Dur-
ing the last ten years 1,500 pregnant MS patients were pro-
spectively enrolled in the registry and at least 250 new 
pregnancies	are	followed	every	year.	These	six	registries	make	
an	important	epidemiological	and	scientific	contribution.	Nu-
merous colleagues from clinics and practice support these 
registries.	The	objective	is	the	closer	understanding	of	the	dis-
ease	course,	the	influence	of	therapeutic	decisions	and	thus	
the improvement of counseling and care.
nomenology, prognostic implications, frequency of tumor associ-
ation and response to therapies is a task that can only be 
particularly	addressed	by	large	clinical	registries.	German	patients	
are distinctly underrepresented in current international cohorts 
[4].	The	German	Network	for	Research	of	Autoimmune	Encephali-
tis	(Deutsche	Netzwerk	zur	Erforschung	Autoimmuner	Enzepha-
litiden)	–	GENERATE,	founded	in	2014,	has	the	goal	to	improve	
treatment	of	autoimmune	encephalitis.	Achieving	this	objective	
requires research of risk factors, causes, mechanisms and progres-
sion	of	the	disease.	GENERATE	should	be	considered	as	(1)	clinical	
platform	for	networking	healthcare	centers	in	Germany,	(2)	point	
of	contact	for	patients	and	relatives	to	find	out	regional	contact	
persons,	and	(3)	scientific	platform	for	collecting	clinical	and	par-
aclinical	data	and	biomaterials	to	support	scientific	research	ap-
proaches. For this purpose, a representative interactive homepage 
(www.generate-net.de)	was	created,	an	internet-based	communi-
cation forum was set up for members, a national patient registry 
was established, central and decentralized biomaterial collections 
were organized, and diagnostic and therapeutic standards were 
developed.
Structure
The	GENERATE	registry	contains	a	retrospective	as	well	as	a	pro-
spective cohort study, and was created as a multicenter study with 
41	active	centers	at	present,	35	of	which	are	actively	recruiting	(see	
also ▶Fig. 1 and 2).
The	registry	includes	male	and	female	patients	of	all	ages	(es-
pecially	children	and	non-consentable	patients	after	clarification	
to	a	legal	guardian)	with	a	clinical	syndrome	of	autoimmune	en-
cephalitis	(e.	g.,	anti-NMDA	receptor	encephalitis,	limbic	enceph-
alitis,	brain	stem	encephalitis)	(1)	with	demonstration	of	a	specific	
autoantibody in the CSF and/or serum or a hippocampal antibody 
with	unknown	specificity	or	(2)	clinical/paraclinical	indication	of	
immune-mediated	genesis	(response	to	immunosuppression,	in-
trathecal immunoglobulin synthesis, and/or CSF pleocytosis, typ-
ical	MRI	changes	such	as	bitemporal	T2/FLAIR	hyperintensities).
Included patients are locally pseudonymised and documented 
using a server-based database. Epidemiological, clinical and para-
clinical data as well as therapies are recorded. All patients whose 
Introduction
Registry	studies	have	the	advantage	of	flexibility,	longevity	and	ac-
quisition of large amounts of data in a relatively short period of time 
compared to clinical trial interventions, without much loss of evi-
dence.	They	are	particularly	suited	to	document	rare	diseases	and	
pathologies	as	well	as	side	effects,	or	to	characterize	special	patient	
cohorts which cannot be included in clinical intervention studies 
(such	as	pregnant	women).	In	the	past	10	years	several	neuroim-
munological	registries	have	been	created	in	Germany.	Numerous	
neurologists in clinics and practices across the country support reg-
istry activities by referring relevant patients. In this article we would 
like	to	present	six	neuroimmunological	registries	for	different	dis-
orders	(autoimmune	encephalitis,	neuromyelitis	optica	spectrum	
disorders	and	multiple	sclerosis),	with	different	key	subjects	(pro-
gression,	documentation	of	side	effects,	immunotherapies,	desire	
to	have	children)	(▶Table 1).	The	registry	structures	will	be	pre-
sented as well as initial results and an outlook on further planned 
evaluations will be provided.
Deutsches Netzwerk zur Erforschung 
autoimmuner	Enzephalitiden	(GErman	
NEtwork	for	Research	on	AuToimmune	
Encephalitis:	GENERATE)
Goals
Autoimmune	encephalitis	is	a	rare	inflammatory	disease	of	the	cen-
tral	nervous	system	which,	however,	causes	significant	mortality,	
and above all morbidity and associated high socioeconomic costs 
[1].	In	recent	years,	the	field	has	experienced	dynamic	development	
by the pioneering description of synaptic autoantibodies as bio-
markers and, in all likelihood, by disease-causing agents [2]. On the 
one hand, the discovery of new synaptic antibodies allows a per-
sistent	therapeutic	and	prognostic	sub-	and	reclassification	of	au-
toimmune encephalitis syndromes [3]; on the other hand, the rapid 
growth of knowledge represents a diagnostic challenge for clini-
cians and scientists. Due to the rarity of the individual encephalit-
ic syndromes, the more precise characterization of clinical phe-
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symptoms began more than three months prior to inclusion are 
placed in a retrospective cohort, while patients exhibiting clinical 
symptoms within the previous three months prior to inclusion are 
grouped in a prospective cohort. Follow-up examinations are per-
formed according to clinical criteria, generally every 3–6 months. 
Biomaterials	(CSF,	serum,	DNA,	CSF	and	blood	cells)	are	preserved	
either	centrally	or	decentrally	and	are	available	for	scientific	projects.
Scientific	analyses	are	carried	out	(1)	as	registry-wide	evalua-
tions of clinical and epidemiological as well as prognostic research 
E27
▶Table 1 Overview of neuroimmunological registries.
Registry Disease Focus Number of cases Goals
GENERATE Autoimmune encephalitis Symptomology, 
treatment, progression
570 Epidemiology, progression, prognosis and care 
of patients with autoimmune encephalitis in 
Germany
NEMOS/
NationNMO
Neuromyelitis optica 
spectrum diseases
Symptomology, treatment 
and progression; 
comparison with MS 
(NationMS)
Approx. 250 Continuing education, consulting and support 
of primary care physicians, patients and 
relatives, multi-sector networking of treating 
physicians
NationMS Clinically isolated syndrome, 
relapsing-remitting multiple 
sclerosis
Long-term observation of 
initially untreated patients 
in early disease stages
1,124 in original 
cohort; recruiting 
(MRI	cohort)	
ongoing
Detailed standardized clinical and paraclinical 
data and biomaterial collection as the basis for 
answering	clinical	and	scientific	questions,	risk	
and biomarker discovery and validation
MS registry 
of	the	DMSG
Multiple sclerosis, clinically 
isolated syndrome
Care monitoring and 
(future)	PRO
Approx. 10,000 
patients/year
On average  > 2.5 
contacts/patient 
per year
Monitoring of care of persons with MS; 
long-term observation of progression 
(therapies);	temporal	changes	in	population;	
patient inclusion, recruitment and research 
platform
REGIMS Multiple sclerosis, clinically 
isolated syndrome
Pharmacovigilance To	date	700	(in	
development)
Pharmacovigilance	of	MS	medication;	nature	
and	frequency	of	side	effects	to	improve	safety	
of medications
DMSKW Multiple sclerosis, clinically 
isolated syndrome, 
neuromyelitis optica
Pregnancy Approx. 1,500 Safety of immune modulating therapies during 
pregnancy and lactation, disease progression 
during pregnancy and postpartum
▶Fig. 1	 GENERATE	centers	in	Germany,	November	2016.
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▶Fig. 2	 Structure	of	the	GENERATE	network.
Thiel S et al. Neuroimmunological Registries in Germany. Neurology International Open 2018; 2: E25–E29
Review
E28
on	behalf	of	the	GENERATE	study	group,	or	(2)	as	single	projects	of	
individual centers with the possibility of an opt-out provision for 
each	individual	center.	The	structure	and	agreements	within	the	
network have been stipulated in a business regulation.
Results
As of September 2016, 570 patients have been documented in the 
GENERATE	registry.	An	initial	epidemiological	evaluation	is	in	
preparation.	An	interim	analysis	shows	that	of	393	patients	(April	
2016),	61	(15.5	%)	suffer	from	seronegative,	and	332	(84.5	%)	suf-
fer from seropositive autoimmune encephalitis. Anti-N-me-
thyl-D-aspartate	receptor	(NMDAR)	encephalitis	represented	the	
most	common	seropositive	group	(34.9	%),	followed	by	GAD-AK-as-
sociated	encephalitis	(15.4	%),	followed	by	Lgi1	encephalitis	
(15.1	%)	and	CASPR2	encephalitis	(7.5	%).	Nine	percent	of	seropos-
itive autoimmune cases demonstrated prognostically unfavorable 
encephalitis	with	antibodies	to	intracellular	antigens	(paraneoplas-
tic	encephalitis)	(unpublished	results	by	Luise	Röpke	for	the	GEN-
ERATE	network).
Outlook
Current	research	projects	are	investigating	the	genetic	predisposi-
tion	of	autoimmune	encephalitis,	associated	cerebrospinal	fluid	dis-
orders and intensive medical complications, morphological image 
and neuropsychological aspects as well as therapeutic response 
rates. Likewise promising are an evaluation of long-term process-
es, investigation of patients with early escalation of immunothera-
py as well as prognostic biomarkers in autoimmune encephalitis.
In	February	2017,	the	non-profit	GENERATE	e.V.	was	founded	as	
the organizer and sponsor of the network with the aim of continu-
ing the existing structures. Expansion of the network to centers in 
Austria and Switzerland is in preparation.
Registry for Neuromyelitis Optica 
 Spectrum diseases
Goals
Neuromyelitis	optica	(NMO,	Devic	syndrome),	has	been	considered	
an	independent	disease	after	identification	of	a	target	antigen	–	
the	water	channel	Aquaporin-4	(AQP4)	[5–7],	which	should	be	dif-
ferentiated	from	multiple	sclerosis	(MS)	with	respect	to	symptoms,	
prognosis	and	therapy	[8].	Antibodies	to	AQP4	(AQP4-AK,	synonym	
NMO-IgG)	are	detectable	in	NMO	(but	not	in	MS)	in	up	to	80	%	of	
all patients [6, 9]. However, NMO is a rare and, to date, little known 
disease pattern, which should be particularly distinguished from 
MS	because	of	the	therapeutic	consequences.	Thus,	therapeutics	
used	in	MS,	e.	g.,	interferon-β	preparations	[10]	can	have	a	nega-
tive	effect	on	NMO	[11].	In	addition,	the	NMO-IgG/AQP-AK	marker	
has led to new diagnostic criteria for NMO [12] or NMO spectrum 
disease,	which	can	be	defined	when,	in	addition	to	a	positive	AQP4-
AK serostatus, there is evidence of a primary clinical criterion such 
as optic neuritis, myelitis, cerebral stem syndrome, dysphoric syn-
drome or an unusual cerebral lesion. An additional immunological 
heterogeneity is to be assumed with NMOSD: antibodies against 
the	myelin	oligodendrocyte	glycoprotein	(MOG)	seem	to	play	a	rel-
evant	role	in	approximately	20–25	%	of	NMOSD	patients	without	
evidence	of	anti-AQP4-AK.
Against the backdrop of these developments, the Neuromyeli-
tis	optica	Study	Group	(German:	Neuromyelitis	optica	Studien-
gruppe,	NEMOS)	was	founded	in	Berlin	in	2008,	with	the	following	
main	objectives:
1)	Networking	of	regional,	national	and	international	clinical	and	
scientific	activities	relating	to	NMO	for	medical	colleagues	and	
patients.
2)	Complete	(initially	retrospective,	in	the	course	also	prospective)	
recording	of	German	verified	and	probable	NMO	cases	in	order	
to obtain important information on the epidemiology and the 
clinical course of the disease.
3)	Collection	of	biomaterials	from	NMO	patients	(blood,	cerebro-
spinal	fluid)	for	scientific	studies	(e.	g.,	comparison	of	different	
methods	for	detecting	AQP4-AK,	and	as	needed,	development	
of	new	assays,	genetic	and	immunological	investigations).
4)	 Initiation	of	common	therapy	studies.
5)	Development	and	publication	of	recommendations	for	diagno-
sis and treatment.
Structure
In 2008 NEMOS was established as a cross-sector network orient-
ed	toward	clinical	neuroimmunology	designed	specifically	to	ad-
dress physicians active in outpatient and inpatient treatment and 
are	interested	in	clinical	and	scientific	issues	relating	to	NMO.	In	
total, more than two dozen clinics, medical centers and practices 
are	incorporated	into	NEMOS	(▶Fig. 3);	on	the	website	www.
nemos-net.org their activities are recapitulated by two NEMOS co-
ordinators	(currently	T.	Kümpfel,	Ludwig-Maximilians-Universität	
Munich,	and	O.	Aktas,	Heinrich-Heine-Universität	Düsseldorf).	
NEMOS also considers itself vertically open within the medical care 
hierarchy, thus providing opportunities for younger scientists to 
address	relevant	issues.	Until	recently,	scientific	inquiry,	content	
coordination and public relations work were carried out on a vol-
untary	basis	without	structural	or	financial	support,	thus	priority	
was given to retrospective cross-sectional and longitudinal analy-
ses based on existing documentation. Since 2016 NEMOS has been 
supported	by	the	German	Federal	Ministry	for	Education	and	Re-
search	(BMBF)	as	a	project	within	the	Competence	Network	Multi-
ple	Sclerosis	(German:	Kompetenznetzwerk	Multiple	Sklerose,	
KKNMS)	for	the	purpose	of	developing	a	national	cohort	(Nation-
NMO)	with	standardized	annual	examination	intervals.	With	regard	
to interaction with patients as well as with the wider medical pro-
fession/care structure, emphasis is placed on the website, contri-
butions to patient forums and events, the involvement of patient 
organizations as well as information and training programs for neu-
rologists	and	psychiatrists.	The	NEMOS	website,	www.nemos-net.
org,	maintained	by	the	University	Clinic	Düsseldorf	is	certified	ac-
cording to the “Health on the Net” code of conduct for medical and 
health websites, directed toward patients and relatives, interested 
medical personnel as well as the NEMOS centers themselves.
The	original	NEMOS	cohort	accepted	patients	with	NMO,	isolat-
ed	myelitis	and	optic	neuritis	with	AQP4	seropositivity.	The	Nation-
NMO cohort will include patients with NMOSD according to current 
diagnostic	criteria	(IPND	2015),	excluding	patients	with	MS	or	with	
isolated myelitis with MS-typical lesion distribution in a cranial MRI.
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The	original	NEMOS	cohort	recruited	all	NMSOD	patients	includ-
ing those with only single examinations. In the NationNMO cohort 
there will be a prospective examination of patients with incidental 
NMOSD	as	those	with	prevalent	NMSOD.	Thus	the	NationNMO	co-
hort will represent a formal subgroup of the NEMOS cohort.
The	original	NEMOS	cohort	relied	on	a	non-time-limited	collec-
tion of basal clinical data for diagnostics and therapy within the 
scope	of	neurological	routine	care,	as	needed	(after	identifying	rel-
evant	clinical	samples),	as	well	as	a	subsequent	expansion	of	data	
collection	on	an	individual	project	basis.
In the NationNMO cohort, a prospective, standardized annual 
clinical and paraclinical data collection will be performed, designed 
to last 6 years, taking into account established parameters and 
scales:	central	collection	of	AQP4	and	MOG	serostatus;	Expanded	
Disability	Status	Scale	(EDSS);	Multiple	Sclerosis	Functional	Com-
posite	Score	(MSFC);	American	Spinal	Injury	Association	Impair-
ment	Scale	(AIS);	Multiple	Sclerosis	Inventory	Cognition	(MUSIC);	
Symbol	Digit	Modalities	Test	(SDMT);	Beck	Depression	Inventory	
(BDI);	Pain	Detect,	Functional	Assessment	of	MS	(FAMS);	High	and	
Low	Contrast	Visual	Acuity;	VEP;	Optical	Coherence	Tomography	
(OCT).
Results
Public	relations
Regarding public relations work, relevant stakeholders have been 
gradually approached over the past eight years and the understand-
ing of NMOSD has been deepened as a rare but relevant disease. In 
concrete terms, it was possible to inform interested parties through 
patient events, and through the opportunity of direct contact via 
the NEMOS website, as well as providing support and advice to care 
providers, while directing them to local NMO specialists. Direct 
support opportunities for patients and relatives could be realized 
through participation in the medical advisory board of patient or-
ganizations	such	as	Transverse	Myelitis	e.V.	and	involvement	in	rel-
evant patient forums. Since its founding in 2008, NEMOS has reg-
ularly organized NMO-oriented symposia and workshops for phy-
sicians and other medical personnel at the annual conferences of 
the	German	Neurological	Society	(DGN),	and	has	been	recognized	
for	this	effort	(Felgenhauer	Prize	2014).	The	two	consensus	papers	
on the diagnosis and therapy of NMO should be considered a sign 
of	these	intensive	coordinated	efforts	[11,	13],	which	currently	are	
among the most cited overview articles in this area.
Scientific activity and original work
Since creating its database in 2008, NEMOS has established the 
basis for a number of recognized and internationally published pa-
pers on relevant aspects of the diagnosis and treatment of NMOSD. 
The	first	study	investigated	the	initial	cohort	of	175	NMO	patients	
as	to	their	demographic,	clinical	and	imaging	findings	with	regard	
to	AQP4	serostatus	[8].	In	parallel,	a	subgroup	of	patients	in	this	
cohort	was	identified	that	was	initially	misdiagnosed	as	relaps-
ing-remitting MS and were routinely put on a high-dose MS ther-
apy with natalizumab [14]; despite this, the patients continued to 
exhibit	persistent	related	disease	activity	[15,	16].	This	difficult	di-
agnosis following a somewhat circuitous route was documented 
in an article on patients who initially underwent a spinal biopsy 
(which	was	in	some	cases	not	acceptably	tolerated)	for	a	suspect-
ed malignant spinal tumor, but who in the end had apparent tume-
factive	longitudinal	extensive	transverse	myelitis	(LETM)	[17].	Fur-
thermore, patients with unusual manifestations of NMOSD in late 
life stages were described using the NEMOS database [18]; addi-
tionally	the	influence	of	gender	on	clinical	aspects	of	NMSOD	was	
characterized [19]. In 2015 NEMOS was able to make a substantial 
contribution regarding acute therapy of NMSOD relapse by demon-
strating the early importance of plasma separation/immune ad-
sorption in particular for longitudinal extensive transverse myelitis 
(LETM)	[20].	Finally,	in	2016	NEMOS	addressed	the	importance	of	
a	systematic	approach	to	anti-MOG	antibodies,	describing	clinical,	
imaging, demographic and immunological aspects [21, 22], as well 
as characterizing brain stem encephalitis which frequently accom-
panies this NMSOD variant [23].
Networking internationally
Right	from	the	start	NEMOS	was	engaged	in	scientific	exchange	
with European and international NMSOD networks. In particular, 
the	initiative	of	the	Guthy-Jackson	Foundation	and	the	regular	
	scientific	conferences	organized	by	this	organization	should	be	
mentioned here. In this context, the path to a common global 
 database for the comprehensive documentation of patients was 
outlined, and increasingly the influence of environmental and 
 lifestyle aspects as well as genetic factors were discussed. It should 
be pointed out that in certain regions such as far east Asia NMOSD 
occurs much more frequently and does not have the status of a rare 
disease [24].
▶Fig. 3	 NEMOS	centers	in	Germany,	November	2016.
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Outlook
NEMOS	has	firmly	established	itself	as	a	clinical-scientific	network	
since	its	founding	in	2008.	The	focus	of	current	NEMOS	activities	
is the expansion of a central patient database which allows simple 
input and maintenance of NMOSD patient data on the Internet, 
while	adhering	to	legal	and	ethical	regulations.	This	project	is	sup-
ported by the inclusion of NEMOS as a new partner in the 
BMBF-funded	KKNMS	(as	"NationNMO	cohort"),	which	is	currently	
in	its	third	funding	phase.	This	grant	is	intended	to	support	data-
base-based, standardized patient documentation, fund a clini-
cal-scientific	comparison	of	the	progression	of	the	diseases	and	dif-
ferentiation from MS as a direct reference disease while establish-
ing a central biobank concept. In summary, NEMOS was embedded 
in already existing sustainable structures which made continuation 
of the NEMOS registry possible.
Prospective	Cohort	Study	of	Clinically	
isolated Syndrome and Early Multiple 
Sclerosis	Performed	by	the	Competence	
Network	Multiple	Sclerosis	(NationMS)
Goals
MS	is	the	most	common	chronic-inflammatory	disease	of	the	cen-
tral nervous system in Central Europe. In 2010, based on data of 
the	statutory	health	insurers	in	Germany,	a	total	of	199,505	MS	pa-
tients	were	identified,	resulting	in	a	prevalence	of	289	per	100,000	
population	[25].	The	estimated	overall	prevalence	over	the	past	
three decades is 83 patients per 100,000 population [26]. MS dis-
ease frequency is higher the more northwards the country is locat-
ed	[27].	The	validation	of	established	risk	factors,	whether	genetic	
or environmental, and uniform data of treatment monitoring algo-
rithms	can	only	be	derived	to	a	limited	extent	from	German	co-
horts, since standardized data and biomaterial collections from 
large	German	multicenter	surveys	are	largely	lacking.	This	resulted	
in	the	initiative	of	the	KKNMS	to	promote	a	German	cohort	study	
for	patients	with	clinically	isolated	syndrome	(CIS)	and	early	MS,	of	
which recruitment started in 2010.
Structure
NationMS is a prospective observational longitudinal cohort study 
(ethics	vote	Ruhr-University	Bochum,	no.	3714-10).
Inclusion	and	exclusion	criteria	are	broadly	defined	in	order	to	
map	the	spectrum	of	the	disease	(▶Table 2 and 3).
Since 2010, patients with CIS and early relapsing-remitting MS 
(RRMS)	have	been	included	in	22	university	and	non-university	
centers	across	Germany.
The	study	is	designed	for	a	total	duration	of	at	least	10	years,	
with the aim of long-term observation and clinical and paraclinical 
characterization of the patients. Study participants are examined 
in	annual	visits	over	the	first	three	years	and	subsequently	every	
second	year	(▶Fig. 4).	A	deviation	of	3	months	from	the	scheduled	
visit date is accepted.
In addition to the collection of basic demographic and clinical 
data and patient questionnaires, standardized clinical and paraclin-
ical assessment scales are implemented including the assessment 
of the domains of disability, cognition, depression, fatigue and 
pain. Following the consented standardized operating procedure 
(SOP),	cranial	MRI	and	asservation	of	biomaterial	are	performed	at	
defined	visits.
The	comprehensive	data	protection	concept	is	based	on	the	
	generic	data	protection	concepts	of	the	Telematics	Platform	for	
Medical	Research	Networks	(TMF),	which	have	been	coordinated	
with	the	Working	Group	for	Science	of	the	federal	data	protection	
authorities	of	the	Federal	Republic	of	Germany	[31].	The	coordi-
nating	center	of	the	NationMS	cohort	(Department	of	Neurology,	
▶Table 2	 NationMS	cohort	study	inclusion	criteria	(CIS	=	clinically	
isolated	syndrome;	RRMS	=	relapsing-remitting	MS,	2a	and	2b	
	alternatives).
NationMS cohort study inclusion criteria
1)	Age		≥		18	years/male	and	female	patients
2a)	Diagnosis	of	CISwithin	6	months	prior	to	inclusion
▪	fulfilling	3	of	4	Barkhof	criteria	[28] 
OR 
▪		fulfilling	2	of	4	Barkhof	criteriaplus	positive	CSF	findings	 
(intrathecal	igG	production/oligoclonal	bands)
OR 
▪  meeting 2 of 4 Barkhof criteriaplus pathological visual evoked 
potentials	(suggestive	of	MS)
OR 
▪	fulfilling	2010	McDonald	criteria	[29]	for	RRMS
2b)	Diagnosis	of	RRMS	according	to	2005	McDonald	criteria	[30]	 
within 24 months prior to inclusion
3)	Therapy-naïve	for	disease-modifying	therapies	(irrespective	of	
relapse	treatment)
▶Table 3 NationMS cohort study exclusion criteria.
NationMS cohort study exclusion criteria
Primary	progressive	multiple	sclerosis	(PPMS)
Other progressive neurological disorders
Relevant	contraindications	for	regular	assessments	(e.	g.,	MRI)
Screening
Baseline
Follow-Up Phase
Year
0 1 2 4 6 8 10
▶Fig. 4 NationMS cohort study design.
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St.	Josef-Hospital	Bochum,	Ruhr-University	Bochum)	performs	
standardized and independent monitoring and review of data.
Results
Recruitment
From August 2010 to December 2014, 1,212 patients were includ-
ed in the NationMS cohort. Due to screening failure or incomplete 
data,	88	patients	(7.3	%)	were	excluded,	resulting	in	1,124	patients	
of the original cohort with evaluable records of the baseline visit 
(▶Table 1).	960	patients	have	undergone	their	first	follow-up	
	examination	(year	1).	The	subsequent	follow-up	examinations	 
(year	2)	are	in	progress	in	2016.	Since	2015,	further	recruitment	
has been carried out for an extended MRI cohort in centers with 
3-Tesla	MRI.	So	far,	172	patients	have	been	included	in	this	subco-
hort	(as	of	02-Nov-2016).
Analysis of the baseline visits show a gender distribution of 2.2: 
1	(female	n	=	775;	male	n	=	349).	The	diagnosis	is	CIS	in	44.6	%	of	
patients	(n	=	501)	and	RRMS	in	55.3	%	of	patients(n	=	622).	Age	at	
first	clinical	presentation	(CIS	and	RRMS)	is	median	31.71	years	(IQR	
26.06–40.33),	age	at	diagnosis	(only	RRMS)	is	31.67	years	(IQR	
26.50–40.33).
Scientific activities, original articles, public relations
In addition to the evaluation of baseline clinical data, large-scale 
genetic	projects	have	already	been	significantly	supported	with	
DNA material of the cohort and successfully published [32, 33]. 
Nine	risk	genes	within	the	human	leukocyte	antigen	(HLA)	region	
and seven outside the HLA region were thus replicated within this 
German	population	[32].	In	a	further	study,	four	new	susceptibili-
ty	genes	were	identified;	their	genetic	products	seem	to	be	in-
volved in epigenetic regulation [33].
In	addition	to	scientific	investigations,	the	collaboration	within	
the KKNMS has led to consented recommendations addressing 
therapy monitoring for immunotherapies as well as the issue of the 
change	of	therapy	[34,	35].	This	contributes	to	improvement	of	pa-
tient safety and possibly therapy optimization.
Outlook
The	NationMS	cohort	is	a	unique	large,	multicenter	and	well-de-
fined	long-term	study	of	patients	with	CIS	and	RRMS	with	stand-
ardized clinical and paraclinical assessment and biomaterial. At 
present, the detailed analysis of baseline data including demogra-
phy	and	disease	characteristics	of	this	German	MS	cohort	is	ongo-
ing. Further follow-up and ongoing recruitment are crucial for con-
tinued long-term observation.
Further	current	projects	investigate	relationships	between	clin-
ical parameters and established environmental markers with the 
use of biomaterial. For example, an investigation of vitamin D sta-
tus within the cohort as well as research of viral factors are running. 
Several groups are focused on the analysis of MRI parameters. Mul-
ticenter evaluations of large patient numbers are facilitated by the 
consensus MRI protocol.
The	NationMS	cohort	facilitates	ongoing	and	planned	longitu-
dinal and cross-sectional investigations. Due to the high number 
of	participants,	both	subgroup	analyses	of	defined	patient	groups	
and	large-scale	projects	are	possible.	The	availability	of	standard-
ized data, biomaterial and MRI data will further expand over time. 
The	NationMS	cohort	has	thus	special	significance	for	the	further	
acquisition of knowledge in MS. Hopefully, these results will rapid-
ly	find	their	way	into	clinical	routine	in	order	to	improve	diagnosis,	
therapy	and	care	of	MS	patients	in	Germany;	this	has	already	begun	
as a result of collaborative work within the network via practice-re-
lated publications.
The	MS	Registry	of	the	DMSG
Despite high and increasingly more expensive costs for the treat-
ment	and	support	of	those	suffering	from	MS,	as	well	as	the	pre-
mature exit from employment of patients with MS, there is still lit-
tle reliable information on prevalence of disease types or the care 
situation	of	persons	with	MS	in	Germany.	Because	of	this,	in	2001	
the	German	Multiple	Sclerosis	Society	(Deutsche	Multiple	Sklero-
se	Gesellschaft,	Bundesverband	e.V.,	DMSG)	established	an	MS	reg-
istry	as	a	long-term	project	in	order	to	collect	and	analyze	data	ob-
tained	nationwide.	The	MS	registry	 is	managed	by	the	MS-
FP-gGmbH1 as an independent entity under the sponsorship of the 
DMSG,	and	has	continued	to	grow	since	its	founding	(see	▶Fig. 5).
Goals
The	initial	aim	of	the	registry	was	to	establish	a	uniform,	reliable	
overview	of	MS	in	Germany	for	the	first	time,	thus	demonstrating	
potential needs of people with MS. For this purpose, data were col-
lected	and	evaluated	regarding	a)	disease	course,	b)	distribution	
according	to	severity,	c)	employability,	d)	care	aspects,	e)	regional	
distribution	and	f)	therapies	[36–42].
From 2014 to today: new 
infrastructure and PRO
2010 to 2013: Revision of data model 
and infrastructure – common DMSG and 
KKNMS basic data set – web-based 
documentation software
2004 to 2010: Expansion phase – extension of 
documentation country-wide across 150 centers 
for all care areas – standardized quality reviews
2001 to 2003: Startup phase – principles established 
for uniform documentation of MS with five different 
care areas
▶Fig. 5 Developmental phases of the MS registry since founding 
2001 until now [source-supplied illustration].
1		MS	Forschungs-	und	Projektentwicklungs-gGmbH	a	100	%	subsidiary	of	the	
DMS	Stiftung	of	the	DMSG,	BV	e.V.
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As part of a comprehensive revision in cooperation with the In-
stitute for Medical Informatics of the University Medical Center 
Göttingen,	the	registry	was	methodically	revised	until	2014,	both	
in terms of its infrastructure and the applied data set.
The	current	goal	of	the	MS	registry	is	to	establish	a	permanent	
data repository for care research based on the over 10 years of 
 experience. It will ensure the collection, storage and provision of 
data regarding MS patients over decades, and present long-term 
courses	of	the	disease	as	well	as	monitor	the	care	of	those	suffer-
ing from MS.
The	revision	laid	the	foundation	for	achieving	participatory	data	
collection [43], which includes both physicians and patients in data 
collection.	Thus,	the	registry	can	support	scientific	research	pro-
jects,	for	example,	by	using	the	data	to	generate	hypotheses	and	
to	respond	to	these	specific	issues	[44].	Furthermore,	the	registry	
will support the exchange of data with other national and interna-
tional MS repositories. Such collaborations will more intensively 
compare	regional	aspects	or	opportunities	of	different	health	sys-
tems, so that the requirements of individualized medical research 
can be better addressed.
5.2 Structure
The	MS	registry	of	the	DMSG	Bundesverband	e.V.	is	a	German	
Patient	Registry	with	the	following	existing	inclusion	criteria:
 ▪ Written	informed	consent	(after	explanation	by	the	center)
 ▪ Verified	MS	(according	to	McDonald	or	Poser)	with	selected	
disease course OR CIS
 ▪ Primary	domicile	in	Germany
The	MS	registry	has	developed	a	nationwide	network	of	MS	centers	
including all areas2	of	care	(see	▶Fig. 6)	that	recruit	MS	patients	
for	the	registry.	These	centers	are	awarded	by	the	DMSG	Bun-
desverband	e.V.3.	The	broad	network	enables	the	included	patients	
to be comprehensively documented crossing center and sector bar-
riers, thus supporting the current focus on longitudinal observa-
tion of disease progression.
The	centers	involved	in	the	MS	registry	are	currently	being	mi-
grated from decentralized data collection to a centralized, web-
based	documentation	platform.	The	previously	documented	data	
are being transferred to the new infrastructure using a migration 
tool. After two years of transition, since the fourth quarter of 2016, 
the new data set and the documentation in the web-based research 
database are obligatory for all centers. In addition to the web-based 
data entry, documentation can be performed in third-party sys-
tems which are connected via an appropriate interface to the re-
search database.
The	web-based	solution	made	it	possible	to	significantly	reduce	
the	IT	requirements	in	the	individual	centers	compared	to	using	a	
decentralized	software	application.	Only	a	PC	or	tablet	connected	
to the Internet is necessary to access the documentation platform. 
Corrections	or	additions	to	the	data	set	(for	example,	newly	ap-
proved	active	substances	and	supplementary	items)	can	now	be	
performed centrally and made available to all centers simultane-
ously without delay. Same goes for updates of the platform.
In the web-based research database, the centers receive feed-
back on their documentation via checks of established value rang-
es, plausibility and cross-references in the event of discrepancies. 
These	checks	are	supplemented	by	subsequent	reviews	of	the	 
total	data	pool.	Queries	regarding	the	documented	data	arising	
during monitoring are send out to the centers as integrated que-
ries in the research database and can be answered directly there. 
An audit trail is also available and allows the tracking of changes to 
the data.
The	data	in	the	registry	is	collected	prospectively	and	multi-cen-
trically. It includes data from routine examinations of MS patients. 
Patient	documentation	is	recurrent	and	consists	of	several	mod-
ules	that	are	filled	out	in:
 ▪ Baseline documentation: including basic data such as gender, 
age, initial symptoms and onset of the disease.
 ▪ and continuous follow-up documentations: comprising 
long-term data on the course of the disease and care of the 
respective patient.
▶Fig. 6	 Distribution	of	centers	in	Germany	as	of	10/01/2016	[map	
data	©	2016	GeoBasis-DE/BKG	(©2009),	Google,	Inst.	Geogr.	Na-
cional].
2  74 MS specialty centers, 80 MS centers and 19 MS rehabilitation centers 
(as	 of	 01/13/2017)	 |	 map	 at	 https://www.dmsg.de/msregister/index.
php?nav	=	zentren
3 https://www.dmsg.de/service/kliniken-praxen/dmsg-ausgezeichnete-zen-
tren/
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Currently	the	data	to	be	documented	is	based	on	a	data	set	jointly	
stipulated	by	DMSG	and	KKNMS,	as	well	as	the	recommendations	
of	the	EUReMS	project	for	the	creation	of	a	minimum	data	set,	and	
includes registry-related additions. In an expansion module, select-
ed centers document the current therapy as well as the history of 
the	patients’	therapeutic	modifications.	In	the	future,	PRO	data	
(e.	g.,	Health	Related	Quality	of	Life,	HRQoL)	which	are	increasing-
ly	required	to	support	scientific	research	questions	and	health	pol-
icy will be linked to clinical data in the MS registry. During the revi-
sion, purely clinical data collection was expanded to include the 
patient’s	perspective.	Variables	of	supplementary	issues	can	be	
modularly included in the registry documentation, and the result-
ing data can be used together with the core data to respond to 
these questions.
The	concept	of	the	MS	registry	has	been	reviewed	by	various	eth-
ics	committees.	Patient	participation	in	the	registry	is	voluntary	and	
can	be	terminated	at	any	time.	The	MS	registry	is	registered	under	
the	number	DRKS00011257	in	the	German	Clinical	Trials	Register.
The	registry	follows	the	structure	illustrated	in	▶Fig. 7 which 
has been implemented in accordance with the generic data pro-
tection	concepts	of	the	TMF	e.V.	A	strict	separation	of	identifying	
data	(IDAT)	and	medical	data	is	maintained.	A	link	between	the	
pseudonymized medical and identifying data is only possible for 
the treatment centers in which the patient has given his/her con-
sent to registering.
▶Table 4 Registry population demographic data as of September 
2016.
Demographic Data
Age 
(years)
Duration 
of MS 
(years)
EDSS 
score 
(median)
Female
Total	data
(n	=	48,386)
45.9 ± 12.1 12.8 ± 9.7 3 70.8	%
Relapsing- 
remitting 
MS
(n	=	27,764)
42.3 ± 10.8 10.5 ± 7.9 2 73.6	%
Secondary 
progressive 
MS
(n	=	11,492)
53.4 ± 10.3 20.5 ± 9.8 6 67.5	%
Primary	
progressive 
MS
(n	=	3,480)
55.5 ± 10.8 14.7 ± 10.0 5.5 58.2	%
Clinically 
isolated 
syndrome
(n	=	1,767)
37.8 ± 11.2 2.6 ± 3.6 1.5 69.7	%
▶Fig. 7 Inclusion of centers and patients in the documentation of the MS registry in relation to the underlying infrastructure [source-supplied 
illustration][44].
4		The	following	figures	represent	registry	data	as	of	September	2016
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Results
The	MS	registry	answered	for	the	first	time	important	questions	
regarding	the	situation	of	patients	with	MS	in	Germany.	Starting	in	
2005, the initial results4 were published regarding the uniform data 
set	resulting	from	the	Germany-wide	survey,	providing	informa-
tion regarding distribution according to gender, forms of progres-
sion,	symptoms,	age	at	disease	onset	(average:	32.9	years),	initial	
symptoms	and	time	to	diagnosis	(average	2.7	years).	See	also	ex-
cerpts of registry data in ▶Table 4. Furthermore, the type of care, 
the	utilization	(and	discontinuation)	of	therapies	and	aids	could	be	
evaluated	for	the	first	time	based	on	nationwide	data	collection.	In	
addition,	the	registry	provides	data	regarding	the	effects	of	MS	on	
employment [37–41, 45]
Based on the initial data obtained from the new registry infra-
structure,	the	issue	arising	as	a	result	of	Petersen	et	al.	[46]	was	an-
swered: whether the proportion of patients with primary progres-
sive	MS	(PPMS),	who	receive	a	therapy	to	modify	the	course	of	the	
disease contrary to the current guidelines, is also accounted for in 
the registry. Our evaluation showed a similarly high proportion of 
patients	with	PPMS	receiving	therapy.	However,	we	were	able	to	
demonstrate that compared to earlier observations [40] the pro-
portion has decreased [47].
In addition to cross-sectional observations, the MS registry of-
fers	the	capability	of	long-term	observations.	The	number	of	pa-
tients with coherent documentation over a 3 or 6-year period is 
being continuously expanded and currently stands at more than 
8,300 and 1,000 data sets. In 20155 visits for more than 12,700 pa-
tients were documented. On average there were more than two 
consultations per patient in 2015.
The	MS	registry	is	open	for	research	and	collaborative	projects6. 
For example, available data can be used during the planning phase 
of	research	projects	to	generate	hypotheses,	which,	based	on	the	
new infrastructure and the modular data set can be answered as a 
supplementary	question	via	the	registry	platform	[44].	The	MS	reg-
istry has already successfully established data exchange at the na-
tional and European level.
Outlook
The	available	data	are	currently	being	used	for	additional	issues,	
including “benign MS” and symptoms and provision of therapy, and 
are available for publication.
In the future, reports should regularly be provided to the docu-
menting centers as an overview of their respective populations 
compared to the total population or the population range under 
care, thus supplementing the already available statistics and re-
ports	in	the	research	database.	A	related	pilot	project	is	currently	
underway, providing the centers with a better overview of their pa-
tient	data.	In	this	way,	for	example,	special	characteristics	(e.	g.,	in-
creased	proportion	of	progressive	patients)	can	be	identified.	In	
the past, such data have already been requested by the centers in 
order to answer, for example, inquiries regarding internal and ex-
ternal quality control.
Based	on	the	experiences	of	a	first	pilot	phase	for	the	web-	and	
app-based	recording	of	PRO	data	[50],	a	concept	is	currently	being	
developed to involve patients in the registry documentation in the 
long	term.	A	further	field	of	action	is	the	provision	of	data	regard-
ing	the	safety	of	disease-modifying	therapies	(DMTs).	In	the	Euro-
pean	network,	the	German	MS	registry	is	working	with	other	MS	
registries to establish a system to provide the supervisory author-
ities with uniform data for the assessment of the safety of MS med-
icines.
REGIMS	Immunotherapy	Registry
Goals
The	drug	market	for	indication	of	MS	is	very	dynamic	since	many	
new medications have been approved in recent years. New approv-
als	concerned	in	particular	the	field	of	highly	active	immunothera-
pies	[48].	Additional	Phase	III	studies	have	been	completed	or	are	
still underway [49] so that additional approvals can be expected in 
coming	years.	While	frequent	side	effects	are	usually	recognized	
prior	to	approval	in	Phase	II	and	III	studies,	less	common	side	effects	
are often not known at the time of approval because of limited pa-
tient	numbers.	An	efficient	post-approval	pharmacovigilance	sys-
tem is therefore of great importance. Since the immune system is 
the focal point for many new medications to treat MS, long-term 
effectiveness	as	well	as	side	effects	of	the	therapy	are	relevant	to	
ensure	the	efficacy	and	safety	of	the	drug.	The	primary	objective	
of	REGIMS	is	therefore	the	establishment	of	a	long-term	immuno-
therapy registry for recording the incidence, type and characteris-
tics of adverse events of current and future immunotherapeutic 
agents in MS therapy. Secondary goals include analysis of factors 
that	increase	the	risk	of	drug	side	effects	as	well	as	those	associat-
ed with good therapy adherence.
Structure
The	registry	includes	patients	with	a	confirmed	MS	diagnosis	or	CIS	
patients who are at least 18 years of age and who meet the follow-
ing	inclusion	criteria:	patients	treated	for	the	first	time	with	an	im-
munotherapeutic	agent	(de	novo	patients),	or	those	treated	with	
natalizumab,	fingolimod,	alemtuzumab,	mitoxantron,	terifluno-
mide, dimethyl fumarate, daclizumab or a drug released in the fu-
ture regardless of duration of therapy; or those who have been 
treated with interferons, glatiramer acetate or azathioprine for a 
maximum of 36 months.
REGIMS	is	a	multicentric	registry	of	the	KKNMS,	which	is	coor-
dinated	at	the	Westfälische	Wilhelms-Universität	Münster.	Partic-
ipating centers are clinics, MS outpatient clinics and MS specialty 
centers that include patients in routine screening.
Data collection includes electronic documentation of medical 
parameters collected at participating centers by trained personnel 
as	well	as	patient	documentation	in	which	the	patient	fills	out	a	
questionnaire.	The	basic	medical	documentation	includes	current	
and previous MS therapies, comorbidities, EDSS scores, relapses 
and	any	pregnancies.	The	patients	are	tracked	by	follow-up	every	
six	months.	The	medical	follow-up	documentation	includes	relaps-
es since the last examination, changes in MS therapy, reasons for 
discontinuation of therapy, adverse and serious adverse events as 
well as pregnancies. In addition, the patient receives questions on 5  Data collection and assessment for 2016 is not yet complete.
6		Please	direct	related	questions	to	the	MSFP	(msregister@dmsg.de).
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the quality of life, therapy adherence and various lifestyle factors 
at 6-month intervals.
To	reduce	duplicate	documentation	and	to	take	advantage	of	
existing	systems,	three	different	input	options	are	available	for	elec-
tronic	documentation	in	the	centers;	these	include	secuTrial®,	
MSDS	3D®	as	well	as	System	x4T	which	was	specially	developed	for	
REGIMS.	All	REGIMS	registry	data	are	finally	stored	in	the	central	
KKNMS	database.	Due	to	their	participation	in	REGIMS,	all	centers	
are also cooperation partners of the KKNMS.
Unwanted events of current and future immunotherapeutic 
agents	are	thus	detected	at	an	early	stage	(typically	at	occurrence)	
and	reported	to	the	manufacturers.	The	narrow	time	frames	for	the	
documentation as well as a parallel survey of both patient and phy-
sician	guarantee	this.	This	makes	an	overall	picture	of	the	disease	
and patient situation possible. In addition, centers and their pa-
tients have the option to participate in the biobank of the KKNMS. 
For this purpose, there is a separate consent procedure and a stand-
ardized method for blood collection and shipment. After accept-
ance, patients are monitored for the long term and surveyed at reg-
ular	intervals.	The	registry	therefore	makes	a	key	contribution	to	
the	drug	safety	of	MS	patients.	The	registry	is	registered	under	the	
number	in	the	German	Registry	of	Clinical	Studies.
Results
After successful establishment of the immunotherapy registry since 
the	start	of	the	project	in	2013,	the	number	of	new	participating	
centers is steadily rising, and new patients are increasingly includ-
ed in the respective centers. In addition, the semiannual medical 
follow-up surveys are carried out in the centers, allowing the de-
scription	of	medical	information	regarding	MS	therapy	(including	
changes	in	therapy),	the	course	of	the	disease,	side	effects	and	co-
morbidities. At the same time, every six months participating pa-
tients record their own experiences, such as quality of life, therapy 
satisfaction,	therapy	adherence	and	side	effects	from	their	person-
al perspective.
January	2013	was	the	initiation	of	REGIMS.	As	of	01/01/2017,	
36	centers	are	active	participants	in	REGIMS,	with	inclusion	of	over	
700 patients. In the course of the coming months additional 
centers	will	join.
Outlook
Establishment of a pharmacovigilance database for MS medications 
is	significant	due	to	the	approval	of	numerous	new	drugs	to	treat	
MS as well as the fact that additional medicines are in the approval 
process.	An	immunotherapy	registry	offers	important	advantages,	
especially	with	respect	to	the	long-term	effects	of	medicinal	prod-
ucts. Country-wide recruiting of additional centers is currently in 
progress. In addition, collaboration with the MSBase international 
registry	(www.msbase.org)	[50]	is	in	preparation	as	well	as	with	the	
Swedish	MS	registry	SMSreg	[51]	so	that	side	effects	can	be	record-
ed, assessed and reported on a broad basis.
Deutsches Multiple Sklerose und 
	Kinderwunschregister	(DMSKW)	 
(German	MS	and	Pregnancy	Registry)
Goals
In recent years, only a few diseases have experienced such a great 
expansion of therapeutic possibilities as MS with the immunomod-
ulatory	therapies.	Since	the	affected	persons	are	primarily	young	
women,	the	objective	of	the	German	MS	and	Pregnancy	registry	
(DMSKW),	founded	exactly	10	years	ago,	is	to	obtain	safety	infor-
mation	regarding	drug	exposure	during	pregnancy.	Since	effec-
tive	contraceptive	measures	are	required	for	all	DMTs	not	only	dur-
ing clinical trials, but also after market introduction, only limited 
data are available on the risks of exposure during pregnancy and 
lactation.	To	assess	the	safety	of	DMT	exposure	during	pregnan-
cy,	the	European	Medicines	Agency	(EMA)	requires	at	least	300,	
but	preferably	1,000	prospective	pregnancies	with	first	trimester	
exposure.	These	large	numbers	of	cases	are	only	available	for	sub-
stances	with	long-term	experience	such	as	interferon-β	[52]	and	
glatiramer acetate [53]. Data on more than 300 pregnancies was 
collected	for	natalizumab	[54]	and	fingolimod	[55]	exposed	preg-
nancies.	There	is	insufficient	experience	with	newer	substances	
such as teriflunomide, dimethyl fumarate, alemtuzumab and 
 daclizumab to evaluate the safety of exposure to these therapies 
during pregnancy.
In addition to safety aspects, the course of MS during pregnan-
cy	and	postpartum	as	well	as	the	identification	of	modifiable	risk	
factors	affecting	relapse	are	of	interest.	The	typical	course	of	MS	
during pregnancy is well known, with a reduction of relapse rate 
up	to	80	%	during	the	last	trimester	of	pregnancy,	followed	by	a	sig-
nificant	increase	during	the	first	6	months	postpartum	[56],	and	
has	been	reproducibly	confirmed	multiple	times	[57,	58].	Howev-
er,	the	influence	of	various	different	DMTs	or	the	discontinuation	
of such therapies before a planned pregnancy on relapse during 
pregnancy	and	postpartum	has	not	been	sufficiently	investigated	
yet. It is known that after discontinuation of natalizumab severe 
rebound relapses can occur [59, 60], and that they can also occur 
during	pregnancy,	despite	its	protective	effect	[61].	Whether	this	
also	applies	to	other	DMTs	which	are	used	for	highly	active	disease	
progression requires further examination. Some studies have 
shown	that	DMT	therapy	prior	to	pregnancy	can	reduces	the	risk	
of	relapse	during	the	first	three	months	postpartum	[62–64].
The	aim	of	the	DMSKW	is	to	find	the	best	possible	treatment	
regimen for MS patients with the desiring to have children in order 
to minimize the risk for both, mother and child.
Structure
The	DMSKW	is	a	prospective	cohort	study	of	pregnant	MS	patients.	
Every year, approximately 250 pregnant women with CIS, clinical-
ly	verified	MS	or	NMO	are	admitted	to	the	registry	at	any	time	dur-
ing pregnancy. Similar to an embryotoxicological advisory insti-
tute, the registry is contacted by treating neurologists, gynecolo-
gists, pediatricians, MS nurses, but also by patients themselves with 
questions regarding pregnancy and MS, especially regarding deal-
ing	with	MS	therapies	before,	during	and	after	pregnancy.	The	ma-
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jority	of	women	become	aware	of	the	DMSKW	through	advertise-
ments in articles of magazines, publications on the homepage 
of	 the	DMSG,	or	 via	 the	homepage	of	 the	DMSKW	 (www.
ms-und-und-chinderwunsch.de)	or	they	are	actively	recruited	by	
their	neurologists	or	MS	nurses.	Physicians	or	MS	nurses	are	in-
formed	via	publications	in	journals	or	advanced	training	courses.	
Data is collected in standardized interviews, generally by tele-
phone.	To	avoid	recall	bias,	interviews	are	conducted	once	during	
every remaining trimester after study entry and in months 1, 3, 6, 
12	and	24	postpartum	(see	▶Fig. 8).	In	addition	to	basic	charac-
teristics of the mother, all data pertaining to drug exposure prior 
and during pregnancy is collected, as well as information relating 
to	progression	of	the	disease,	pregnancy	and	birth.	Progression	of	
MS as well as child development are surveyed up to 2 years after 
birth.	To	limit	information	bias,	data	were	obtained	from	official	
documents such as the maternity log, the child examination record 
as well as the vaccination record. In case of negative pregnancy out-
comes or occurrence of MS relapses during pregnancy or postpar-
tum, gynecologists, pediatricians and neurologists are contacted 
to verify the collected data. All congenital malformations are as-
sessed	and	classified	by	a	teratologist	of	the	Mainz	birth	registry	
according to the current European surveillance of congenital ab-
normalities	(EUROCAT)	guidelines.
Results
In recent years, the DMSKW was able to answer many practically 
relevant questions by targeted data evaluation, and thereby to con-
tribut the improvement of the care of MS patients desiring children.
Thus,	further	confirmation	could	be	provided	that	exposure	to	
glatiramer	acetate	[65],	interferon-β	[66]	or	natalizumab	[67]	dur-
ing	the	first	trimester	of	pregnancy	does	not	increase	the	risk	of	a	
negative pregnancy outcome, compared to pregnancies not ex-
posed	to	DMTs.	These	results	reflect	the	pharmacologically	plausi-
ble	safety	of	exposure	to	glatiramer	acetate,	interferon-β	or	natal-
izumab during early pregnancy.
In a case series of 13 pregnancies of 12 women with highly-ac-
tive MS treated with natalizumab during the third trimester, 10 out 
of 13 newborns had mild to moderate anomalies such as anemia, 
thrombocytopenia or leukocytosis [68].
Women who discontinued natalizumab therapy prior to a 
planned	pregnancy	suffered	relapses	more	frequently	during	preg-
nancy	than	women	who	discontinued	this	therapy	during	the	first	
trimester	after	confirmation	of	pregnancy	[69].
Furthermore, the evaluation of women with moderate disease 
activity, who breastfed exclusively, partially breastfed or who did 
not breastfeed at all indicated that only exclusive breastfeeding re-
duced postpartal relapse activity [70], resulting in the hypothesis 
that the anti-ovulation factor, together with pronounced hormo-
nal	changes	contributes	to	this	effect.	In	addition	it	was	observed	
that the reduction of relapse activity ends with the introduction of 
supplemental feeding.
In	recent	years	the	findings	of	the	DMSKW	have	been	able	to	im-
prove the counseling and care of MS patients worldwide wishing 
to	become	pregnant.	Thus	the	summary	of	product	characteristics	
of natalizumab has included a statement regarding hematological 
abnormalities after exposure during the third trimester and result-
ing necessity for related monitoring, and most recently, the abso-
lute	contraindication	for	the	use	of	glatiramer	acetate	(Copaxone®	
20	mg)	during	pregnancy	has	been	removed.
Outlook
Although the DMSKW has contributed substantially to the improve-
ment of MS patients with the desire to have children, a number of 
questions	remain	unanswered	such	as	the	risk	of	interferon-β	or	
glatiramer acetate exposure during the second and third trimes-
ters of pregnancy. In addition, the risk of exposure to newer ther-
apies	such	as	teriflunomide,	dimethyl	fumarate,	alemtuzumab	and	
daclizumab	during	the	first	trimester	needs	to	be	studied.	Also	of	
great interest is the risk of relapse after discontinuation of MS ther-
apy prior to a planned pregnancy, especially with respect to women 
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▶Fig. 8	 Phases	of	the	pregnancy	registry	during	pregnancy	and	postpartum.
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with highly active diseases. It may be feasible to reduce relapses 
during pregnancy and lessen the need for high doses of glucocor-
ticoids by maintaining MS therapy until the onset of pregnancy. 
Low	doses	of	prednisolone	(20	mg)	are	associated	with	a	risk	of	cleft	
palate [71]. It is still unknown whether high dose treatments 
(1000	mg)	are	associated	with	the	risk	of	other	abnormalities.	It	is	
also unclear whether exclusive breastfeeding also has a positive ef-
fect on the risk of relapse in women with highly active disease as 
well	as	the	effects	of	DMT	exposure	during	lactation	on	the	infant.	
The	influence	of	DMT	exposure	during	pregnancy	is	also	uncertain	
on the development and health of children up to the preschool age. 
To	date,	the	DMSKW	has	collected	data	on	the	development	and	
health of 232 small children in an unsystematic, cross-sectional ob-
servation. In the long term, however, it is planned to expand sys-
tematic DMSKW data collection to a 6-year follow-up.
Conclusions
Observational studies are an important part of epidemiological re-
search. Registry studies have become an indispensable means of 
gaining knowledge, especially regarding data collection within spe-
cific	patient	groups,	such	as	patients	with	very	rare	diseases	(or-
phan	diseases)	or	pregnant	women.	The	most	important	advan-
tages of these studies include the possibility to make statements 
about the progress of the disease in connection with therapeutic 
decisions	and	the	related	spectrum	of	side	effects,	multicentric	col-
laboration as well as the support of registry work by contributions 
by	colleagues	in	practice	and	research.	Significant	scientific	ques-
tions can be answered through the collection of clinical data in 
combination with radiological or serological parameters.
Over the past 10 years the six registries presented in this article 
have	established	themselves	across	Germany,	providing	prac-
tice-related results not only for neurologists but also for those af-
fected	by	neurological	diseases.	The	findings	based	on	these	reg-
istries are almost unique and therefore of great importance espe-
cially for patients suffering from rare NMOSD or autoimmune 
encephalitis, but also for the special patient group of women with 
MS who wish to become pregnant.
All neuroimmunological registries presented here work closely 
with colleagues in research and practice, engage actively in public 
relations while making available relevant results at national and in-
ternational	conferences	as	well	as	publishing	in	medical	journals.	
Consequently,	these	research	groups	not	only	provide	a	scientifi-
cally	valuable	contribution	but	also	positively	influence	both	the	
counseling	and	care	of	the	affected	patient	groups.
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